Cargando…
Current state of CAR-T therapy for T-cell malignancies
Chimeric antigen receptor T-cell (CAR-T) therapy has been approved for relapsed/refractory B-cell lymphomas and greatly improves disease outcomes. The impressive success has inspired the application of this approach to other types of tumors. The relapsed/refractory T-cell malignancies are characteri...
Autores principales: | Luo, Liangkui, Zhou, Xuan, Zhou, Lijuan, Liang, Zhao, Yang, Jilong, Tu, Sanfang, Li, Yuhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806442/ https://www.ncbi.nlm.nih.gov/pubmed/36601636 http://dx.doi.org/10.1177/20406207221143025 |
Ejemplares similares
-
CAR T-cell therapy for follicular lymphoma and mantle cell
lymphoma
por: Mohty, Razan, et al.
Publicado: (2022) -
The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
por: Albanyan, Omar, et al.
Publicado: (2022) -
Recent advances in immunotherapy for B-cell non-Hodgkin lymphoma and multiple myeloma
por: Chavez, Julio C., et al.
Publicado: (2022) -
Prognostic and clinicopathological impacts of systemic immune-inflammation index on patients with diffuse large B-cell lymphoma: a meta-analysis
por: Fan, Zaijing, et al.
Publicado: (2023) -
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
por: Sanchez, Larysa, et al.
Publicado: (2021)